Cargando…
A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges
BACKGROUND: Regional citrate anticoagulation (RCA) is proposed for various extracorporeal purification techniques to overcome the risk of bleeding that might result from systemic anticoagulation. Yet, no individualized treatment protocol has been proposed for therapeutic plasma exchange (TPE) so far...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333425/ https://www.ncbi.nlm.nih.gov/pubmed/28249613 http://dx.doi.org/10.1186/s12882-017-0494-9 |
_version_ | 1782511705701482496 |
---|---|
author | Kissling, Sébastien Legallais, Cécile Pruijm, Menno Teta, Daniel Vogt, Bruno Burnier, Michel Rondeau, Eric Ridel, Christophe |
author_facet | Kissling, Sébastien Legallais, Cécile Pruijm, Menno Teta, Daniel Vogt, Bruno Burnier, Michel Rondeau, Eric Ridel, Christophe |
author_sort | Kissling, Sébastien |
collection | PubMed |
description | BACKGROUND: Regional citrate anticoagulation (RCA) is proposed for various extracorporeal purification techniques to overcome the risk of bleeding that might result from systemic anticoagulation. Yet, no individualized treatment protocol has been proposed for therapeutic plasma exchange (TPE) so far. The objective of this study was to assess the determinants of blood citrate concentration needed and to develop an individualized RCA protocol useful for clinical practice. METHODS: The study population included 14 patients who underwent a total of 47 TPE sessions. Citrate was infused pre-plasmafilter. Post-plasmafilter and systemic plasma ionized calcium concentrations were measured at standardized time intervals. An algorithm was proposed for the supplementation of calcium. During the discovery phase, citrate was infused at a fixed starting rate, and adapted accordingly to obtained post-plasmafilter ionized calcium levels. Using a mathematical approach, an algorithm was thereafter developed for individualized prescriptions of citrate. RESULTS: Pre-treatment values of hematocrit and plasma ionized calcium were the main determinants of the required rate of citrate infusion. These can be integrated into a final equation enabling to individualize the prescription. A prefilter ionized calcium concentration between 0.24 and 0.33 mmol/l prevented coagulation of the extracorporeal circuit. Significant hypocalcemia occurred in 8.5% of treatments. There were no significant acid–base disturbances. CONCLUSION: We propose a new protocol, which enables for the first time to individualize the prescription of regional citrate anticoagulation during TPE, in an efficient manner. The immediately obtained regional anticoagulation protects against both the risk of coagulation of the membrane and the exposure to an excess of citrate. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0494-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5333425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53334252017-03-06 A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges Kissling, Sébastien Legallais, Cécile Pruijm, Menno Teta, Daniel Vogt, Bruno Burnier, Michel Rondeau, Eric Ridel, Christophe BMC Nephrol Technical Advance BACKGROUND: Regional citrate anticoagulation (RCA) is proposed for various extracorporeal purification techniques to overcome the risk of bleeding that might result from systemic anticoagulation. Yet, no individualized treatment protocol has been proposed for therapeutic plasma exchange (TPE) so far. The objective of this study was to assess the determinants of blood citrate concentration needed and to develop an individualized RCA protocol useful for clinical practice. METHODS: The study population included 14 patients who underwent a total of 47 TPE sessions. Citrate was infused pre-plasmafilter. Post-plasmafilter and systemic plasma ionized calcium concentrations were measured at standardized time intervals. An algorithm was proposed for the supplementation of calcium. During the discovery phase, citrate was infused at a fixed starting rate, and adapted accordingly to obtained post-plasmafilter ionized calcium levels. Using a mathematical approach, an algorithm was thereafter developed for individualized prescriptions of citrate. RESULTS: Pre-treatment values of hematocrit and plasma ionized calcium were the main determinants of the required rate of citrate infusion. These can be integrated into a final equation enabling to individualize the prescription. A prefilter ionized calcium concentration between 0.24 and 0.33 mmol/l prevented coagulation of the extracorporeal circuit. Significant hypocalcemia occurred in 8.5% of treatments. There were no significant acid–base disturbances. CONCLUSION: We propose a new protocol, which enables for the first time to individualize the prescription of regional citrate anticoagulation during TPE, in an efficient manner. The immediately obtained regional anticoagulation protects against both the risk of coagulation of the membrane and the exposure to an excess of citrate. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0494-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-01 /pmc/articles/PMC5333425/ /pubmed/28249613 http://dx.doi.org/10.1186/s12882-017-0494-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Technical Advance Kissling, Sébastien Legallais, Cécile Pruijm, Menno Teta, Daniel Vogt, Bruno Burnier, Michel Rondeau, Eric Ridel, Christophe A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges |
title | A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges |
title_full | A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges |
title_fullStr | A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges |
title_full_unstemmed | A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges |
title_short | A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges |
title_sort | new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges |
topic | Technical Advance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333425/ https://www.ncbi.nlm.nih.gov/pubmed/28249613 http://dx.doi.org/10.1186/s12882-017-0494-9 |
work_keys_str_mv | AT kisslingsebastien anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT legallaiscecile anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT pruijmmenno anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT tetadaniel anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT vogtbruno anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT burniermichel anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT rondeaueric anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT ridelchristophe anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT kisslingsebastien newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT legallaiscecile newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT pruijmmenno newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT tetadaniel newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT vogtbruno newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT burniermichel newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT rondeaueric newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges AT ridelchristophe newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges |